Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Feature|Articles|September 29, 2025
What urologists can expect in Q4 of 2025
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A comprehensive guide to the key regulatory decisions and conferences slated for the last few months of the year.
Advertisement
Advertisement
As we enter the final months before the end of 2025, we reflect on the notable advances that have already shifted the landscape in urologic care. Looking back at this year, we saw notable approvals across bladder cancer, prostate cancer, and benign conditions.
Related to this article
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
Advertisement
Advertisement